AMAG Pharmaceuticals Inc. (AMAG) Stock Price Down 3.4%
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) fell 3.4% during trading on Wednesday . The company traded as low as $23.43 and last traded at $23.82, with a volume of 307,190 shares. The stock had previously closed at $24.66.
A number of research firms have recently commented on AMAG. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Friday, August 12th. Jefferies Group lowered their target price on AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday, August 10th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $36.78.
The firm’s 50-day moving average price is $24.71 and its 200-day moving average price is $23.79. The company’s market capitalization is $821.75 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/amag-pharmaceuticals-inc-amag-stock-price-down-3-4.html
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. The firm had revenue of $127.40 million for the quarter, compared to the consensus estimate of $128.52 million. AMAG Pharmaceuticals had a positive return on equity of 13.98% and a negative net margin of 4.87%. The company’s quarterly revenue was up 46.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.12 earnings per share. On average, equities research analysts expect that AMAG Pharmaceuticals Inc. will post $5.43 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Palo Alto Investors LLC increased its position in shares of AMAG Pharmaceuticals by 12.6% in the second quarter. Palo Alto Investors LLC now owns 3,273,220 shares of the specialty pharmaceutical company’s stock worth $78,295,000 after buying an additional 367,026 shares during the last quarter. Janus Capital Management LLC increased its position in AMAG Pharmaceuticals by 20.1% in the second quarter. Janus Capital Management LLC now owns 3,222,639 shares of the specialty pharmaceutical company’s stock worth $77,084,000 after buying an additional 538,322 shares in the last quarter. BlackRock Fund Advisors increased its position in AMAG Pharmaceuticals by 2.4% in the second quarter. BlackRock Fund Advisors now owns 3,000,604 shares of the specialty pharmaceutical company’s stock worth $71,774,000 after buying an additional 70,170 shares in the last quarter. Vanguard Group Inc. increased its position in AMAG Pharmaceuticals by 2.3% in the second quarter. Vanguard Group Inc. now owns 2,796,692 shares of the specialty pharmaceutical company’s stock worth $66,897,000 after buying an additional 62,190 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in AMAG Pharmaceuticals by 14.1% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,568,200 shares of the specialty pharmaceutical company’s stock worth $61,431,000 after buying an additional 316,393 shares in the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.